Table 1.

MCL and FL composite lymphomas.

Case number	Age	Involvement	Immunohistochemistry staining	Treatment	Follow-up	Ref
	Gender
1	66 F	Waldeyer ring Tonsil Pharyngeal wall Lingual tonsil Nasal cavity	MCL: CD5+, CD20+, IgD+, cyclinD1+, Bcl-2+, CD3− FL: CD2+, CD10+, Bcl-2+, Bcl-6+, CD5−	Corticosteroid	PET scan every 3–6 months	[2]
2	M	Ocular adnexa	NA	NA	Poor prognosis mentioned	[3]
3	84 F	Spleen	FL: CD20+, CD23+, Bcl-6+, CD5−, CD43−, Bcl-2− MCL: cyclinD1+, CD5−	Splenectomy Patient refused additional treatment	9 months after splenectomy, CT scan showed intra-abdominal lymphadenopathy and patient died from unknown cause 13 months later	[4]
4	70 F	Cervical LN Inguinal LN	CD20+, CD3−, cyclinD1− 50% of B-cell expressed CD5 (MCL) 30% of B-cell expressed CD10 (FL)	No chemotherapy	CT of chest and abdomen showed no evidence of lymphadenopathy or hepatosplenomegaly	[5]
5	65 M	Inguinal LN	FL: CD20+, CD79a+, CD10+, Bcl-2+, CD5−, CD230, cyclinD1−, p27+ MCL: CD20+, CD79a+, CD5+, CD10−, CD23−, cyclinD1+, p27− Interfollicular areas mostly CD5+ showing distinct cylinD1 staining	Splenectomy	MCL caused disease progression into spleen. One year after splenectomy, it achieved stable disease	[6]
6	58 F	Mesenteric LN Small bowel	MCL: CD5+, CD20+, CD43+ FL: CD10+, CD20+, p27+	22 cycles of chemotherapy over 2 years	Complete remission	[7]